Ayala Pharmaceuticals Inc (ADXS)

[DewDiligence]

Another short read on neoantigen vaccines:

https://www.nature.com/articles/d41586-017-08706-3

Clinical researchers see neoantigen vaccines and checkpoint inhibition as complementary treatments that might often be used together, especially for patients with large tumours or metastatic disease. “The neoantigen vaccine is like the steering wheel, to guide the immune response… The checkpoint blockade is removal of the brakes.”

…Until researchers get better at predicting which neoantigens will generate a response, they need to target cancers with a high mutation rate, says Fred Ramsdell, vice-president of research at the non-profit Parker Institute for Cancer Immunotherapy in San Francisco, California. As well as melanoma, that category includes lung, stomach, colorectal and cervical cancers.

Emphasis added.